



## Eastern Pain Association 2019 Fall/Annual Meeting October 5, 2019

### **COURSE DESCRIPTION**

This single-day annual scientific meeting will focus on the latest in pathophysiology, diagnosis and treatment of pain as a disease state. The 2019's US Department of Health and Human Services Task Force Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations will be reviewed. This meeting will highlight the importance of pain and symptom management for varying patient populations (channelopathies, cutaneous pain, knee osteoarthritis, and benzodiazepine withdrawal) through an interdisciplinary approach involving physicians, nurses, other members of the healthcare team, and basic scientists. Looking forward, some innovations in research will be covered, sharing some of the most hopeful new pharmacology coming down the pike. These didactic sessions and one case-based discussion will allow questioning and comment from the attendees, shedding light on complex, chronic pain issues including interface between pain and chemical dependency. Presentations and discussions will be led mostly by experienced faculty with some trainee-led topics.

### **EDUCATIONAL OBJECTIVES**

After participating in this activity, clinicians should be able to:

1. prescribe opioids more safely and more appropriately
2. provide more balanced pain management utilizing multidisciplinary, multimodal pain management
3. Assess risk of dependence using a biopsychosocial model; individualize each patient's pain management

### **TARGET AUDIENCE**

physicians, nurses, other members of the healthcare team, basic scientists.

### **ACCREDITATION STATEMENT**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the NYU School of Medicine and Eastern Pain Association Inc. The NYU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

### **CME CREDIT DESIGNATION STATEMENT**

The NYU School of Medicine designates this live activity for a maximum of *7.00 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **CONTINUING NURSING EDUCATION CONTACT HOURS**

This program will provide 7.00 continuing nursing education contact hours.

The NYU Rory Meyers College of Nursing Center for Continuing Education in Nursing is accredited as a provider of continuing nursing education by the American Nurses®™ Credentialing Center®™s Commission on Accreditation.

### **DISCLOSURE STATEMENT**

The NYU School of Medicine adheres to ACCME accreditation requirements and policies, including the Standards for Commercial Support regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed on the following page.

### **MISSION STATEMENT**

The NYU School of Medicine is committed to training physicians to provide excellent care of patients through life-long continuing medical education of the highest quality. Our overall goal is to enhance clinical competence and performance, and, where possible, improve patient outcomes.

Jointly provided by the NYU School of Medicine and Eastern Pain Association Inc



**NYU School of Medicine  
FULL DISCLOSURE POLICY**

**Eastern Pain Association 2019 Fall/Annual Meeting  
October 5, 2019**

It is the policy of the NYU School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its individually provided or jointly provided activities. Because CME activities are conducted in the public interest, it is important to assure the public that education received by physicians and other health care professionals through whom patient care decisions are made is conducted with the highest integrity, scientific objectivity and in the absence of bias. A conflict of interest exists when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the product or services of that commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) holds providers of CME responsible for collecting information from its instructors, planners and managers of CME content and resolving those conflicts prior to the commencement of the CME activity. The intent of the conflict of interest resolution process is to assure that provider, faculty and planner financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

The following have indicated whether or not they have received financial support for consultation, research or evaluation, have a financial interest relative to their presentation or will include the discussion of the unlabeled or unapproved use of a drug, device or procedure:

<b>Name</b>	<b>Role</b>	<b>Company Name: Type of Relationship</b>
Charles Argoff, M.D.	Speaker	reports no relevant financial relationships.
Nitin Bansal, MD	Panelist	reports no relevant financial relationships.
Michael Caterina, MD, PhD	Speaker	UCSF, Merck - Royalties (not including book royalties)
Kenneth Chapman, MD	Speaker, Panelist	reports no relevant financial relationships.
Maria Carmela Evangelista, DNP	Panelist	reports no relevant financial relationships.
Priyanka Ghosh, MD	Panelist	reports no relevant financial relationships.
Mattia Gilmartin, RN, PhD, FAAN	Planner	reports no relevant financial relationships.
Natasa Grancaric, MD	Panelist	reports no relevant financial relationships.
Robert Griffin, MD	Panelist	reports no relevant financial relationships.
Karina Gritsenko, MD	Planner	reports no relevant financial relationships.
Yili Huang, DO	Panelist	reports no relevant financial relationships.
Charles Inturrisi, PhD	Planner, Moderator	reports no relevant financial relationships.
Jatin Joshi, MD	Panelist	reports no relevant financial relationships.
Andrew Kaufman, MD	Panelist	reports no relevant financial relationships.
Jung Kim, MD	Planner	reports no relevant financial relationships.
Nigel Knox, MD	Speaker	reports no relevant financial relationships.
Peter Lascarides, DO	Speaker	reports no relevant financial relationships.
Anna Li, B.A.	Panelist	reports no relevant financial relationships.
Yan Magram, MD	Speaker	reports no relevant financial relationships.

Diana Mayants, PT, DPT, OCS, CMPT	Panelist	reports no relevant financial relationships.
Neel Mehta, MD	Planner, Moderator	reports no relevant financial relationships.
Debra Miller-Saultz, DNP FNP-BC	Planner, Speaker	reports no relevant financial relationships.
Kristoffer Padjen, MD, PhD	Course Director, Panelist	reports no relevant financial relationships.
Yingxian Pan, M.D., Ph.D.	Speaker	Sparian Biosciences - Other - Scientific founder
William Schmidt, PhD	Planner, Moderator	reports no relevant financial relationships.
Nitin Sekhri, MD	Course Director	reports no relevant financial relationships.
Joseph Seldin, MD, MS	Panelist	reports no relevant financial relationships.
Sapan Shah, MD	Panelist	reports no relevant financial relationships.
Naum Shaparin, MD	Speaker	reports no relevant financial relationships.
Ruchi Sharma, MD	Panelist	reports no relevant financial relationships.
Anand Thakur, MD	Speaker	reports no relevant financial relationships.
Jing Wang, MD, PhD	Panelist	reports no relevant financial relationships.
Stephen Waxman, MD, PhD	Speaker	reports no relevant financial relationships. I will discuss a pharmacogenomically-guided trial of carbamazepine in a small kindred with Inherited Erythromelalgia.
Lisa Witkin, MD	Speaker	reports no relevant financial relationships. topic is for research/innovations: 4:30 – 4:45 PM Subject Matter: Cingal (combination of sodium hyaluronate + triamcinolone hexacetonide; intra-articular injection) knee osteoarthritis, Phase 3 (Approved in Canada)
Ajax Yang, MD	Panelist	reports no relevant financial relationships.
Wei Jie Zhang, M.D	Panelist	reports no relevant financial relationships.
Danielle Milbauer, MBA, CHCP	Planner	reports no relevant financial relationships.
Thomas S. Riles, MD	Planner & Associate Dean for Medical Education and Technology	reports no relevant financial relationships.

The Independent Reviewer of this activity reports no relevant financial relationships.